Serina Therapeutics, Inc. ("Serina") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced ...

Operator: Good afternoon, and welcome to the Cumberland Pharmaceuticals Second Quarter 2025 Financial Report and Company ...

Q2 2025 Management View CEO David L. Hallal emphasized Scholar Rock is “scaling for the next phase of growth as a commercial stage fully integrated global biopharmaceutical company.” He outlined three ...

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero ...

Expanding Nexscient’s Global Portfolio of AI-Powered Platforms and Services LOS ANGELES, CA / ACCESS Newswire / August 6, ...

On June 30, 2025, FDA’s Human Foods Program published its proposed 2025 guidance agenda, including the Agency’s priority ...

ZUSDURITM (mitomycin) for intravesical solution now available as the first and only FDA-approved medication for adults with recurrent lo ...

$5 Million in Funding: In April 2025, Serina secured $5 million from strategic shareholders to support the continued development of SER-252 (POZ-apomorphine), Serina's lead clinical candidate for ...

On June 12, 2025, the U.S. Food and Drug Administration (FDA) approved ZUSDURI (formerly UGN-102), the first and only FDA-approved medication for adults with recurrent LG-IR-NMIBC.

Indivior develops and markets medicines focused on the treatment of addiction and serious mental illness, with a particular emphasis on opioid use disorder (OUD). Its portfolio includes SUBLOCADE, a ...